Intestinal first-pass metabolism of CYP3A4 substrates

Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 2, 2008, Pages 87-94

  Kato, Motohiro ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

CYP3A4; Grapefruit juice; Intestinal metabolism; Prediction

Indexed keywords

ALFENTANIL; ALPRAZOLAM; ATORVASTATIN; BUSPIRONE; CYCLOSPORIN; CYTOCHROME P450 3A4; FELODIPINE; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MIDAZOLAM; NICARDIPINE; NIFEDIPINE; PROPAFENONE; QUINIDINE; RIFAMPICIN; SAQUINAVIR; SILDENAFIL; SIMVASTATIN; TACROLIMUS; TRIAZOLAM; TROLEANDOMYCIN; VERAPAMIL; ZOLPIDEM; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A;

AREA UNDER THE CURVE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; FIRST PASS EFFECT; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; INTESTINE FUNCTION; NONHUMAN; PREDICTION; REVIEW; ANIMAL; BEVERAGE; DRUG ANTAGONISM; GRAPEFRUIT; INTESTINE; METABOLISM; PHYSIOLOGY;

ANIMALS; AREA UNDER CURVE; BEVERAGES; CITRUS PARADISI; CYTOCHROME P-450 CYP3A; ENZYME INDUCTION; HUMANS; INTESTINES;

EID: 43749104916     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.23.87     Document Type: Review

References (73)

1. Wu, C.-Y., Benet, L. Z., Hebert, M. F., Gupta, S. K., Roland, M., Gomez, D. Y. and Wacher, V. J.: Differentiation of absorption and first pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin. Pharmacol. Ther., 58: 492-497 (1995).
2. Thummmel, K. E., O'Shea, D., Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D. and Wilkinson, G. R.: Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther., 59: 491-502 (1996).
3. Lampen, A., Zhang, Y., Hackbarth, I., Benet, L. Z., Sewing, K. F. and Christians, U.: Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol. Exp. Ther., 285: 1104-12 (1998).
4. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesmann, M. M., Pastan, I. and Willingham, M. C.: Cellular localization of the multidrug resistance gene product in normal human tissues. Proc. Natl. Acad. Sci. USA, 84: 7735-7738 (1987).
5. Saito, H. and Aungst, B. J.: Possible involvement of multiple Pglycoprotein-mediated efflux system in the transport of verpamil and other organic cation across intestine. Pharm. Res., 12: 1304-1310 (1995).
6. Wacher, V. J., Wu, C.-Y. and Benet, L. Z.: Overlapping substrate specificities and tissue distribution of cytochrom P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen., 13: 129-134 (1995).
7. Wacher, V. J., Silverman, J. A., Zhang, Y. and Benet, L. Z.: Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidemimetics. J. Pharm. Sci., 87: 1322-1330 (1998).
8. Benet, L. Z., Izumi, T., Zhang Y., Sliverman, J. A. and Wacher, V. J.: Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J. Control. Release, 62: 25-31 (1999).
9. Lin, J. H., Chiba, M. and Baillie, T. A.: Is the role of the small intestine in the first-pass metabolism overemphasized? Pharmcol. Rev., 51: 135-157 (1999).
10. Kaminsky, L. S. and Zhang, Q. Y.: The small intestine as a xenobiotic-metabolizing organ. Drug Metab Dispos, 31: 1520-1525 (2003).
11. Zhang, Q. Y., Dunbar, D., Ostrowska, A., Zeisloft, S., Yang, J. and Kaminsky, L. S.: Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos, 27: 804-809 (1999).
12. Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E. and Zeldin, D. C.: The human intestinal cytochrome P450 "pie". Drug Metab Dispos, 34: 880-886 (2006).
13. Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., Perkins, J. D. and Thummel, K. E.: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther, 283: 1552-1562 (1997).
14. von Richter, O., Burk, O., Fromm, M. F., Thon, K. P., Eichelbaum, M. and Kivisto, K. T.: Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther, 75: 172-183 (2004).
15. Lorn, K. S., Ghsh, M. and Watkins, P. B.: Sequence of intestinal and hepatic cytochrome P450 3A4 cDNA are identical. Drug Metab. Dispos., 26: 185-187 (1998).
16. Lampen, A., Christians, U., Bader, A., Hackbarth, I. and Sewing, K.-F.: Drug interactions and interindividual variability of cyclosporin metabolism in the small intestine. Pharmacology, 52: 159-168 (1996).
17. Galetin, A. and Houston, J. B.: Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther, 318: 1220-1229 (2006).
18. Kato, M., Chiba, K., Hisaka, A., Ishigami, M., Kayama, M., Mizuno, N., Nagata, Y., Takakuwa, S., Tsukamoto, Y., Ueda, K., Kusuhara, H., Ito, K. and Sugiyama, Y.: The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab Pharmacokinet, 18: 365-372 (2003).
19. Higuchi, S. and Shiobara, Y.: Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species. Xenobiotica, 10: 447-457 (1980).
20. Edgar, B., Lundborg, P. and Regardh, C. G.: Clinical pharmacokinetics of felodipine. A summary. Drugs, 34: 16-27 (1987).
21. Bode, H., Brendel, E., Ahr, G., Fuhr, U., Harder, S. and Staib, A. H.: Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine, Eur. J. Clin. Pharmacol., 50: 195-201 (1996).
22. Kharasch, E. D., Walker, A., Hoffer, C. and Sheffels, P.: Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther, 76: 452-466 (2004).
23. Ducharme, M. P., Warbasse, L. H. and Edwards, D. J.: Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther, 57: 485-491 (1995).
24. Lundahl, J., Regardh, C. G., Edgar, B. and Johnsson, G.: Effects of grapefruit juice ingestion-pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol, 52: 139-145 (1997).
25. Kupferschmidt, H.H., Fattinger, K. E., Ha, H. R., Follath, F. and Krahenbuhl, S.: Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol, 45: 355-359 (1998).
26. Edgar, B., Bailey, D., Bergstrand, R., Johnsson, G. and Regardh, C. G.: Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine-and its potential clinical relevance. Eur J Clin Pharmacol, 42: 313-317 (1992).
27. Rashid, T. J., Martin, U., Clarke, H., Waller, D. G., Renwick, A. G. and George, C. F.: Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol, 40: 51-58 (1995).
28. Jetter, A., Kinzig-Schippers, M., Walchner-Bonjean, M., Hering, U., Bulitta, J., Schreiner, P., Sorgel, F. and Fuhr, U.: Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther, 71: 21-29 (2002).
29. Min, D. I., Ku, Y. M., Geraets, D. R. and Lee, H.: Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers. J Clin Pharmacol, 36: 469-476 (1996).
30. Lilja, J. J., Kivisto, K. T. and Neuvonen, P. J.: Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther, 66: 118-127 (1999).
31. Rogers, J. D., Zhao, J., Liu, L., Amin, R. D., Gagliano, K.D., Porras, A. G., Blum, R. A., Wilson, M. F., Stepanavage, M. and Vega, J. M.: Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther, 66: 358-366 (1999).
32. Lilja, J. J., Kivisto, K.T. and Neuvonen, P. J.: Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther, 64: 477-483.(1998).
33. Kupferschmidt, H. H., Ha, H. R., Ziegler, W. H., Meier, P. J. and Krahenbuhl, S.: Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther, 58:.20-28 (1995).
34. Hukkinen, S. K., Varhe, A., Olkkola, K. T. and Neuvonen, P. J.: Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther, 58: 127-131 (1995).
35. Lilja, J. J., Kivisto, K. T., Backman, J. T., Lamberg, T. S. and Neuvonen, P. J.: Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther, 64: 655-660 (1998).
36. Yasui, N., Kondo, T., Otani, K., Furukori, H., Kaneko, S., Ohkubo, T., Nagasaki, T. and Sugawara, K.: Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology (Berl), 139: 269-273 (1998).
37. Kantola, T., Kivisto, K. T. and Neuvonen, P. J.: Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther, 64: 58-65 (1998).
38. Mazzu, A. L., Lasseter, K. C., Shamblen, E. C., Agarwal, V., Lettieri, J. and Sundaresen, P.: Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther, 68: 391-400 (2000).
39. Kivisto, K. T., Lamberg, T. S., Kantola, T. and Neuvonen, P. J.: Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther, 62: 348-354 (1997).
40. Jalava, K. M., Olkkola, K. T. and Neuvonen, P. J.: Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther, 61: 410-415 (1997).
41. Neuvonen, P. J. and Jalava, K. M.: Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther, 60: 54-61 (1996).
42. Kivisto, K. T., Kantola, T. and Neuvonen, P. J.: Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol, 46: 49-53 (1998).
43. Olkkola, K. T., Backman, J. T. and Neuvonen, P. J.: Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther, 55: 481-485 (1994).
44. Ahonen, J., Olkkola, K. T. and Neuvonen, P. J.: Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol, 40: 270-272 (1995).
45. Backman, J. T., Kivisto, K. T., Olkkola, K. T. and Neuvonen, P. J.: The area under the pzlasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol, 54: 53-58 (1998).
46. Kaukonen, K. M., Olkkola, K. T. and Neuvonen, P. J.: Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther, 62: 510-517 (1997).
47. Neuvonen, P. J., Kantola, T. and Kivisto, K. T.: Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther, 63: 332-341 (1998).
48. Varhe, A., Olkkola, K. T. and Neuvonen, P. J.: Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther, 56: 601-607 (1994).
49. Neuvonen, P. J., Varhe, A. and Olkkola, K. T.: The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clin Pharmacol Ther, 60: 326-331 (1996).
50. Luurila, H., Kivisto, K. T. and Neuvonen, P. J.: Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur J Clin Pharmacol, 54: 163-166 (1998).
51. Greenblatt, D. J., Wright, C. E., von Moltke, L. L., Harmatz, J. S., Ehrenberg, B. L., Harrel, L. M., Corbett, K., Counihan, M., Tobias, S. and Shader, R. I.: Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther, 64: 237-247 (1998).
52. Schmider, J., Brockmoller, J., Arold, G., Bauer, S. and Roots, I.: Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. Pharmacogenetics, 9: 725-734 (1999).
53. Gomez, D. Y., Wacher, V. J., Tomlanovich, S. J., Hebert, M. F. and Benet, L. Z.: The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther, 58: 15-19 (1995).
54. Tsunoda, S. M., Velez, R. L., von Moltke, L. L. and Greenblatt, D. J.: Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther, 66: 461-471 (1999).
55. Lee, J. I., Chaves-Gnecco, D., Amico, J. A., Kroboth, P. D., Wilson, J. W. and Frye, R. F.: Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther, 72: 718-728 (2002).
56. Tuteja, S., Alloway, R. R., Johnson, J. A. and Gaber, A. O.: The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation, 71: 1303-1307 (2001).
57. Greenblatt, D. J., von Moltke, L. L., Harmatz, J. S., Mertzanis, P., Graf, J. A., Durol, A. L., Counihan, M., Roth-Schechter, B. and Shader, R. I.: Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin Pharmacol Ther, 64: 661-671 (1998).
58. Schuetz, E. G., Beck, W. T. and Schuetz. J. D.: Modulators and substrates of P-glycoprotein and cytochrome P45034A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol., 49: 311-318 (1996).
59. Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H. P., von Richer, O., Zendler, J. and Kroemer, H. K.: The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest., 104: 147-153 (1999).
60. Villikka, K., Kivisto, K. T., Luurila, H. and Neuvonen, P. J.: Rifampin reduces plasma concentrations and effects of zolpidem. Clin. Pharmacol. Ther., 62: 629-634 (1997).
61. Twum-Barima, Y. and Carruthers, S. G.: Qunidine-rifampin interaction. N Engl J Med, 304(24): 1466-1469 (1981).
62. Villikka, K., Kivisto, K. T., Backman, J. T., Olkkola, K. T. and Neuvonen, P. J.: Triazolam is ineffective in patients taking rifampin. Clin. Pharmacol. Ther., 61: 8-14 (1997).
63. Bornemann, L. D., Min, B. H., Crews, T., Rees, M. M., Blumenthal, H. P., Colburn, W. A. and Patel, I. H.: Dose dependent pharmacokinetics of midazolam. Eur J Clin Pharmacol, 29: 91-95 (1985).
64. Gupta, M., Kovar, A. and Meibohm, B.: The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol, 45: 987-1003 (2005).
65. Carr, B., Norcross, R., Fang, Y., Lu, P., Rodrigues, A. D., Shou, M., Rushmore, T. and Booth-Genthe, C.: Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes. Drug Metab Dispos, 34: 1703-1712 (2006).
66. Warrington, J. S., Shader, R. I., von Moltke, L. L. and Greenblatt, D. J.: In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos, 28: 392-397 (2000).
67. Klippert, P., Borm, P. and Noordhoek, J.: Prediction of intestinal first-pass effect of phenacetin in the rat from enzyme kinetic data-correlation with in vivo data using mucosal blood flow. Biochem Pharmacol, 31: 2545-2548 (1982).
68. Koster, A. S, Hofman GA, Frankhuijzen-Sierevogel, A. C. and Noordhoek, J.: Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. Drug Metab Dispos, 13: 464-470 (1985).
69. Borm, P. J., Frankhuyzen-Sierevogel, A. C., Weller, E. B. and Noordhoek, J.: Absorption and metabolism of hexamethylmelamine and pentamethylmelamine in rat everted perfused gut segments: correlation with in-vivo data. J Pharm Pharmacol, 37: 629-636 (1985).
70. de Vries, M. H., Hofman, G. A., Koster, A. S. and Noordhoek, J.: Absorption and presystemic glucuronidation of 1-naphthol in the vascularly fluorocarbon emulsion perfused rat small intestine. The influence of 1-naphthol concentration, perfusate flow and noradrenaline. Naunyn Schmiedebergs Arch Pharmacol, 340: 239-245 (1989).
71. Shen, D. D., Kunze, K. L. and Thummel, K. E.: Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev, 27: 99-127 (1997).
72. Yang, J., Jamei, M., Yeo, K. R., Tucker, G. T. and Rostami-Hodjegan, A.: Prediction of intestinal first-pass drug metabolism. Curr Drug Metab, 8: 676-684 (2007).
73. Fagerholm, U.: Prediction of human pharmacokinetics-gut-wall metabolism. J Pharm Pharmacol, 59: 1335-1343 (2007).